cKIT Antibody Drug Conjugates Overcoming Imatinib Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly antibody drug conjugates (ADCs), face challenges in identifying effective payloads that can target and inhibit cell proliferation effectively, with limited chemical classes reaching clinical trials, and existing treatments often lead to resistance issues, such as in the case of imatinib-resistant GIST cells.
Innovation Solution
Development of an antibody drug conjugate specifically designed to target the cKIT receptor, comprising an antibody or antigen binding fragment conjugated with a drug moiety via a linker, which binds to the extracellular domain of cKIT, utilizing specific variable regions and linkers to enhance targeting and delivery of cytotoxic agents to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If small molecule inhibitors like imatinib are used to target cKIT, then cell proliferation is significantly reduced, but resistance develops over time due to secondary mutations in cKIT
Solution Approach 1:
The patent uses an antibody as an intermediary to deliver cytotoxic agents to cKIT-positive cells. The antibody specifically binds to cKIT on the cell surface, serving as a targeted delivery vehicle that bypasses the resistance mechanism affecting small molecule inhibitors. This intermediary approach allows the cytotoxic payload to reach its target directly through antibody-mediated cell uptake, avoiding the need for the drug to compete with mutated binding sites.
2Reliability
If naked antibodies are used to target cKIT, then Imatinib-resistant GIST cells show decreased proliferation and cKIT expression, but the therapeutic payload delivery efficiency is limited
Solution Approach 1:
The patent changes the parameters of the antibody by conjugating it with cytotoxic agents to create an ADC. This transformation modifies the antibody's functional properties, adding potent cytotoxic activity while maintaining its targeting capability. The conjugation alters the molecular characteristics of the antibody, enabling it to deliver lethal payloads to cKIT-positive cells that naked antibodies cannot effectively kill.
3Ease of manufacture
If ADCs are developed with novel cytotoxic agents, then effective targeted delivery can be achieved, but identifying suitable drug compound classes remains difficult
Solution Approach 1:
The patent applies local quality by selecting specific cytotoxic agents with particular mechanisms of action (such as microtubule inhibitors, DNA damaging agents, or proteasome inhibitors) that complement the antibody's targeting function. Each cytotoxic class has distinct local properties—different mechanisms of cell killing, different stability profiles, and different activation requirements—that can be matched to specific clinical needs and resistance patterns.
Data Source
AI summary
The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.